Market Cap 274.77M
Revenue (ttm) 129.42M
Net Income (ttm) 17.38M
EPS (ttm) N/A
PE Ratio 18.05
Forward PE 15.83
Profit Margin 13.43%
Debt to Equity Ratio 0.00
Volume 485,700
Avg Vol 852,002
Day's Range N/A - N/A
Shares Out 79.64M
Stochastic %K 37%
Beta 2.08
Analysts Strong Sell
Price Target $11.25

Company Profile

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, in...

Industry: Biotechnology
Sector: Healthcare
Phone: 310 388 6706
Address:
10900 Wilshire Blvd, Suite 600, Los Angeles, United States
tymtested
tymtested Jun. 13 at 9:44 PM
$NAGE if NAGE is still buying back shares then the low price is just fine.
1 · Reply
wycliff
wycliff Jun. 13 at 3:33 AM
$NAGE https://www.medscape.com/viewarticle/inside-quest-make-old-cells-young-again-2026a1000jrf?form=fpf
0 · Reply
wycliff
wycliff Jun. 12 at 7:14 PM
$NAGE https://event.summitcast.com/view/GAjb2PfaSPbv9ViGy3AtzN/guest_book
0 · Reply
wycliff
wycliff Jun. 12 at 8:58 AM
$NAGE https://s205.q4cdn.com/770776702/files/doc_financials/2026/q1/NAGE-Earnings-Presentation-Q1-2026.pdf
1 · Reply
wycliff
wycliff Jun. 12 at 12:54 AM
$NAGE https://www.linkedin.com/posts/nad-nmn-nr-share-7469871877973475330-a73v/?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAAAUGerIBOiyuZoO-6U9HRKRzZ48AD8YnjZA&utm_campaign=share_via
0 · Reply
MattManzanita
MattManzanita Jun. 12 at 12:31 AM
$NAGE The importance of winning the challenge to the FDA regarding its reversal in allowing NMN to be sold OTC is underscored by the cover of Life Extension Magazine, which just arrived. It touts NMN as a less expensive way to raise NAD. Life Extension stayed with Niagen Bio (then Chromadex) when Thorne and Elysium stabbed it in the back. It also indicates the ultimate importance of FDA drug approvals for Niagen. With those, Niagen Bio can make efficacy claims for NR, but NMN sellers in the US will not be able to. It also shows the importance of expanding IV sales. That written, the FDA is not apparently doing anything to restrict NAD IVs, despite those sellers not getting proper regulatory approval. (continued)
2 · Reply
wycliff
wycliff Jun. 12 at 12:08 AM
$NAGE https://www.linkedin.com/posts/stuart-diamond-md-facs-clp-b68556345_longevity-nad-nmn-share-7470466766419197952-PKqb/?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAAAUGerIBOiyuZoO-6U9HRKRzZ48AD8YnjZA&utm_campaign=share_via
0 · Reply
wycliff
wycliff Jun. 11 at 9:02 PM
$NAGE https://x.com/forrest_phd/status/2065083394489217517?s=46&t=__Y6Jc4u9xx6Yl0Ih9I5Fw
0 · Reply
wycliff
wycliff Jun. 11 at 8:59 PM
$NAGE https://x.com/charlesmbrenner/status/2065164447421747578?s=42
0 · Reply
wycliff
wycliff Jun. 11 at 7:16 PM
$NAGE https://www.linkedin.com/posts/niagenbioscience_many-companies-sell-nad-products-we-invent-ugcPost-7470903204021661696-jFMe?utm_medium=ios_app&rcm=ACoAAAUGerIBOiyuZoO-6U9HRKRzZ48AD8YnjZA&utm_source=social_share_video_v2&utm_campaign=copy_link
1 · Reply
Latest News on NAGE
Niagen Bioscience renames CERP to Niagen Research Program

2026-06-02T15:25:33.000Z - 12 days ago

Niagen Bioscience renames CERP to Niagen Research Program


Niagen Bioscience reports Q1 EPS 7c, consensus 6c

2026-05-07T01:51:30.000Z - 5 weeks ago

Niagen Bioscience reports Q1 EPS 7c, consensus 6c


Niagen Bioscience sees 2026 sales growth 10%-15%

2026-05-07T01:50:48.000Z - 5 weeks ago

Niagen Bioscience sees 2026 sales growth 10%-15%


Niagen Bioscience Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 5 weeks ago

Niagen Bioscience Earnings Call Transcript: Q1 2026


Niagen Bioscience Quarterly report: Q1 2026

May 6, 2026, 4:30 PM EDT - 5 weeks ago

Niagen Bioscience Quarterly report: Q1 2026


Niagen Bioscience Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 5 weeks ago

Niagen Bioscience Earnings release: Q1 2026


Niagen Bioscience Slides: Q1 2026

May 6, 2026, 4:30 PM EDT - 5 weeks ago

Niagen Bioscience Slides: Q1 2026


Niagen Bioscience launches Niagen Plus telehealth plarform

2026-05-04T13:07:08.000Z - 6 weeks ago

Niagen Bioscience launches Niagen Plus telehealth plarform


Niagen Bioscience Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 6 weeks ago

Niagen Bioscience Proxy statement: Proxy filing


Niagen Bioscience Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 6 weeks ago

Niagen Bioscience Proxy statement: Proxy filing


Niagen Bioscience increases share repurchase program to $20M

2026-03-19T12:50:32.000Z - 3 months ago

Niagen Bioscience increases share repurchase program to $20M


Niagen Bioscience to Present at the 38th Annual ROTH Conference

Mar 18, 2026, 8:32 AM EDT - 3 months ago

Niagen Bioscience to Present at the 38th Annual ROTH Conference


Niagen Bioscience up 39% at $6.88 after Q4 results and guidance

2026-03-04T21:45:21.000Z - 3 months ago

Niagen Bioscience up 39% at $6.88 after Q4 results and guidance


Niagen Bioscience Earnings Call Transcript: Q4 2025

Mar 4, 2026, 4:30 PM EST - 3 months ago

Niagen Bioscience Earnings Call Transcript: Q4 2025


Niagen Bioscience Annual report: Q4 2025

Mar 4, 2026, 4:30 PM EST - 3 months ago

Niagen Bioscience Annual report: Q4 2025


Niagen Bioscience Earnings release: Q4 2025

Mar 4, 2026, 4:30 PM EST - 3 months ago

Niagen Bioscience Earnings release: Q4 2025


Niagen Bioscience Slides: Q4 2025

Mar 4, 2026, 4:30 PM EST - 3 months ago

Niagen Bioscience Slides: Q4 2025


Niagen Bioscience reports Q4 EPS 5c, consensus 2c

2026-03-04T21:11:47.000Z - 3 months ago

Niagen Bioscience reports Q4 EPS 5c, consensus 2c


Niagen Bioscience Slides: corporate presentation

Mar 4, 2026, 7:00 AM EST - 3 months ago

Niagen Bioscience Slides: corporate presentation


Niagen Bioscience secures new patent for nicotinamide riboside

2026-02-25T13:45:39.000Z - 3 months ago

Niagen Bioscience secures new patent for nicotinamide riboside


Niagen Bioscience Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:30 PM EST - 7 months ago

Niagen Bioscience Earnings Call Transcript: Q3 2025


Niagen Bioscience Earnings release: Q3 2025

Nov 4, 2025, 4:30 PM EST - 7 months ago

Niagen Bioscience Earnings release: Q3 2025


Niagen Bioscience Quarterly report: Q3 2025

Nov 4, 2025, 4:30 PM EST - 7 months ago

Niagen Bioscience Quarterly report: Q3 2025


Niagen Bioscience Slides: Q3 2025

Nov 4, 2025, 4:30 PM EST - 7 months ago

Niagen Bioscience Slides: Q3 2025


Niagen Bioscience Slides: Investor presentation

Nov 4, 2025, 7:00 AM EST - 7 months ago

Niagen Bioscience Slides: Investor presentation


Niagen Bioscience Earnings Call Transcript: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 11 months ago

Niagen Bioscience Earnings Call Transcript: Q2 2025


Niagen Bioscience Earnings release: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 11 months ago

Niagen Bioscience Earnings release: Q2 2025


Niagen Bioscience Quarterly report: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 11 months ago

Niagen Bioscience Quarterly report: Q2 2025


Niagen Bioscience Slides: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 11 months ago

Niagen Bioscience Slides: Q2 2025


Niagen Bioscience Slides: Corporate Presentation

May 9, 2025, 7:00 AM EDT - 1 year ago

Niagen Bioscience Slides: Corporate Presentation


Niagen Bioscience Earnings Call Transcript: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Niagen Bioscience Earnings Call Transcript: Q1 2025


Niagen Bioscience Earnings release: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Niagen Bioscience Earnings release: Q1 2025


Niagen Bioscience Quarterly report: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Niagen Bioscience Quarterly report: Q1 2025


Niagen Bioscience Slides: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Niagen Bioscience Slides: Q1 2025


Niagen Bioscience Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Niagen Bioscience Proxy statement: Proxy Filing


Niagen Bioscience Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Niagen Bioscience Proxy statement: Proxy Filing


Niagen Bioscience Slides: Corporate Presentation

Mar 19, 2025, 8:00 AM EDT - 1 year ago

Niagen Bioscience Slides: Corporate Presentation


ChromaDex to Present at the 37th Annual Roth Conference

Mar 11, 2025, 4:04 PM EDT - 1 year ago

ChromaDex to Present at the 37th Annual Roth Conference


Niagen Bioscience Earnings Call Transcript: Q4 2024

Mar 4, 2025, 4:30 PM EST - 1 year ago

Niagen Bioscience Earnings Call Transcript: Q4 2024


Niagen Bioscience Earnings release: Q4 2024

Mar 4, 2025, 4:30 PM EST - 1 year ago

Niagen Bioscience Earnings release: Q4 2024


Niagen Bioscience Annual report: Q4 2024

Mar 4, 2025, 4:30 PM EST - 1 year ago

Niagen Bioscience Annual report: Q4 2024


Niagen Bioscience Slides: Q4 2024

Mar 4, 2025, 4:30 PM EST - 1 year ago

Niagen Bioscience Slides: Q4 2024


tymtested
tymtested Jun. 13 at 9:44 PM
$NAGE if NAGE is still buying back shares then the low price is just fine.
1 · Reply
wycliff
wycliff Jun. 13 at 3:33 AM
$NAGE https://www.medscape.com/viewarticle/inside-quest-make-old-cells-young-again-2026a1000jrf?form=fpf
0 · Reply
wycliff
wycliff Jun. 12 at 7:14 PM
$NAGE https://event.summitcast.com/view/GAjb2PfaSPbv9ViGy3AtzN/guest_book
0 · Reply
wycliff
wycliff Jun. 12 at 8:58 AM
$NAGE https://s205.q4cdn.com/770776702/files/doc_financials/2026/q1/NAGE-Earnings-Presentation-Q1-2026.pdf
1 · Reply
wycliff
wycliff Jun. 12 at 12:54 AM
$NAGE https://www.linkedin.com/posts/nad-nmn-nr-share-7469871877973475330-a73v/?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAAAUGerIBOiyuZoO-6U9HRKRzZ48AD8YnjZA&utm_campaign=share_via
0 · Reply
MattManzanita
MattManzanita Jun. 12 at 12:31 AM
$NAGE The importance of winning the challenge to the FDA regarding its reversal in allowing NMN to be sold OTC is underscored by the cover of Life Extension Magazine, which just arrived. It touts NMN as a less expensive way to raise NAD. Life Extension stayed with Niagen Bio (then Chromadex) when Thorne and Elysium stabbed it in the back. It also indicates the ultimate importance of FDA drug approvals for Niagen. With those, Niagen Bio can make efficacy claims for NR, but NMN sellers in the US will not be able to. It also shows the importance of expanding IV sales. That written, the FDA is not apparently doing anything to restrict NAD IVs, despite those sellers not getting proper regulatory approval. (continued)
2 · Reply
wycliff
wycliff Jun. 12 at 12:08 AM
$NAGE https://www.linkedin.com/posts/stuart-diamond-md-facs-clp-b68556345_longevity-nad-nmn-share-7470466766419197952-PKqb/?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAAAUGerIBOiyuZoO-6U9HRKRzZ48AD8YnjZA&utm_campaign=share_via
0 · Reply
wycliff
wycliff Jun. 11 at 9:02 PM
$NAGE https://x.com/forrest_phd/status/2065083394489217517?s=46&t=__Y6Jc4u9xx6Yl0Ih9I5Fw
0 · Reply
wycliff
wycliff Jun. 11 at 8:59 PM
$NAGE https://x.com/charlesmbrenner/status/2065164447421747578?s=42
0 · Reply
wycliff
wycliff Jun. 11 at 7:16 PM
$NAGE https://www.linkedin.com/posts/niagenbioscience_many-companies-sell-nad-products-we-invent-ugcPost-7470903204021661696-jFMe?utm_medium=ios_app&rcm=ACoAAAUGerIBOiyuZoO-6U9HRKRzZ48AD8YnjZA&utm_source=social_share_video_v2&utm_campaign=copy_link
1 · Reply
wycliff
wycliff Jun. 10 at 3:10 PM
$NAGE https://www.linkedin.com/posts/reminder-niagen-bioscience-ceo-rob-fried-share-7470490039550980097-ef9x/?utm_source=share&utm_medium=member_ios&rcm=ACoAAAUGerIBOiyuZoO-6U9HRKRzZ48AD8YnjZA
0 · Reply
wycliff
wycliff Jun. 10 at 3:02 PM
$NAGE https://x.com/davidasinclair/status/2064721152778387649?s=42
0 · Reply
MattManzanita
MattManzanita Jun. 9 at 10:20 PM
$NAGE We heard from Rob Fried that the company hopes to expand by perhaps several thousand the number of clinics where Niagen Pus will be available. This is what AI indicates the number of clinics is in the US: AI Overview There are over 7,300 IV therapy providers across 1,100+ cities in the United States. Because these services are offered through independent medical spas, mobile concierge companies, naturopathic doctors, and wellness centers, an exact nationwide count is difficult to track. In Washington State alone, there are approximately 96 registered providers.
2 · Reply
wycliff
wycliff Jun. 9 at 10:09 PM
$NAGE short interest as of May 29 was 4,715,950 down from 4,990,181
0 · Reply
MattManzanita
MattManzanita Jun. 8 at 11:54 PM
$NAGE The number of clinics selling Niagen Plus is up a bit to 1,263. Rob Fried recently mentioned that there are potentially a couple of thousand more places to potentially sell it. He also said that they hope the home injection option will encourage the clinics to drop their prices and increase volume.
0 · Reply
tymtested
tymtested Jun. 8 at 10:58 PM
$NAGE I’m in the red and the stock keeps going down so why am I not worried…..
3 · Reply
wycliff
wycliff Jun. 8 at 10:18 PM
$NAGE https://www.linkedin.com/posts/medspa-longevityclinic-ivtherapy-share-7468351402482778113-fTaW/?utm_source=share&utm_medium=member_ios&rcm=ACoAAAUGerIBOiyuZoO-6U9HRKRzZ48AD8YnjZA
0 · Reply
MattManzanita
MattManzanita Jun. 8 at 5:50 AM
$NAGE This is more rue today than when it was written a year ago: https://www.ainvest.com/news/niagen-bioscience-nad-breakthrough-rare-disease-catalyst-lifesaving-innovation-2506/
4 · Reply
wycliff
wycliff Jun. 7 at 1:29 PM
$NAGE https://finance.yahoo.com/markets/stocks/articles/assessing-niagen-bioscience-nage-valuation-031421713.html
0 · Reply
tymtested
tymtested Jun. 6 at 1:58 PM
$NAGE now if they can just rename the trend of our stock. still holding. BULLISH but in the red.
1 · Reply
wycliff
wycliff Jun. 6 at 12:24 PM
$NAGE correction to earlier post short interest data reported on June9 after 4 pm
0 · Reply
wycliff
wycliff Jun. 5 at 10:31 PM
$NAGE june 8 after 4:00 pm NASDAQ will release short interest data as of May 29 date.It will be interesting to see to see if the short interest continues to decrease.
0 · Reply